BioSwift Talent’s Post

We are excited to share a new paper: “Proline Analogues in Drug Design: Current Trends and Future Prospects”, co-authored by Vladimir Kubyshkin and Pavel Mykhailiuk.   This study examines fluoroprolines, α-methylproline, bicyclic proline analogues, and aminoprolines, while also highlighting underrepresented proline analogues. The analysis includes physicochemical information regarding the specific molecular properties of these moieties. Additionally, it discusses several intriguing cases where nonproline residues were replaced with proline analogues as a strategy to eliminate unwanted hydrogen bond donor sites, and presents some suggestions for the future exploration of this promising class in drug discovery.   Read more: https://lnkd.in/gbzgVXXM

✨ **Excited to Announce a New Publication!** ✨  Proud to share our latest research: **"Innovative Approach of High-Throughput Screening in the Drug Discovery Quest for Chronic Bronchitis Treatment"** 📄 In collaboration with an incredible team, this study explores the power of high-throughput screening (HTS) to identify potential therapeutic compounds for chronic bronchitis. HTS is proving to be an invaluable tool, enabling us to rapidly screen large libraries of compounds and efficiently pinpoint potential treatments. Our hope is that this approach will significantly advance the development of effective therapies for chronic bronchitis, a condition affecting millions worldwide. Thank you to my co-authors Dr. Muhammad Naveed, Khushbakht Javed, Ali Zafar, and everyone involved in making this research possible! For more details, read the full paper (https://lnkd.in/duDbPwPg). #research #drugdiscovery #chronicbronchitis #biotechnology #innovation #teamwork

DRUG DELIVERY, A FORM OF MARKETING! Once you have an active, effective molecule, to be able to make the most of it you need to get it to the target. In recent years, many drug delivery techniques have been developed, such as those aimed to a Tumor-Specific Therapy. Here, by Zijin Li, Hai-Yan Xie and Weidong Niea in ChemMedChem, an update review on Nano-Engineering Strategies in the oncology field. https://lnkd.in/detb3AJC #drugdelivery #Tumor_Specific_Therapy #ChemMedChem 

🌟 Join Us for an Exclusive Webinar! 🌟 Depixus is hosting a webinar on 9/10/24 (9am PT/ 12pm ET/ 6pm CET), entitled “See biology as it really happens – launch of a powerful magnetic force spectroscopy system to enable real-time study of the dynamics of individual molecular interactions at massive scale.” Depixus MAGNA One—the world’s first high-scale magnetic force spectroscopy platform—provides powerful new insights into how biomolecules interact. The technology opens the door to analyzing large numbers of individual interactions in parallel, revealing valuable details otherwise invisible to bulk measurement techniques. In this webinar, part of the MAGNA One commercial launch, Depixus’ CEO, Gordon Hamilton, will highlight this exciting new instrument system and its applications spanning fundamental research to drug discovery. In this webinar you’ll learn how their platform: 🧬Reveals biological variability in stunning detail by repeated analysis of thousands of individual interactions. 🔍 Gathers rich, detailed data from individual biomolecular interactions, revealing rare binding events often missed in bulk measurements. ⏱ Generates both kinetic & thermodynamic data. Don’t miss this chance to elevate your understanding of biomolecular interactions. Whether you’re involved in basic science, applied research, or drug development, the insights gained from Depixus MAGNA One could transform your work! Register here: https://lnkd.in/gzq-v2kx #RNATherapeutics #DrugDiscovery #Biotech #interactomics#Depixus

Our team is proud to contribute to groundbreaking studies in ATP hydrolases, focusing on their essential role in ion transport and cellular homeostasis. Collaborating on this innovative research, we have expanded our expertise in modeling and understanding key molecular interactions. Notably, our work supports the discovery of novel calix[4]arene compounds as selective inhibitors of Mg2+, ATP-dependent electrogenic ion pumps—a promising direction in drug discovery. https://lnkd.in/dAMY7skY 💡 Looking to explore new horizons in computational modeling or virtual screening? Reach out to us for 𝐂𝐀𝐃𝐃 𝐬𝐮𝐩𝐩𝐨𝐫𝐭 and let's achieve breakthroughs together! https://lnkd.in/d_3qGDpJ #DrugDiscovery #CADD #ComputationalChemistry #FundamentalResearch

Our latest article is now online Herein, we report a straightforward technique to design a novel class of physically cross-linked #nanogels by a #selfassembly process in water involving α-cyclodextrin and a mannose molecule that was hydrophobically modified using an alkyl chain. We demonstrated the nanogel's ability to encapsulate a short peptide as a water-soluble #drug model. This discovery holds promise for potentially utilizing these nanogels in drug delivery applications.  Thanks to all the people involved in this collaborative project between Chimie ParisTech - PSL, École normale supérieure, Sorbonne Université, Université PSL and ICSN lab, CNRS - Centre national de la recherche scientifique https://lnkd.in/gckuGAk8

Dr. Olga Tarkhanova and Olena Strapak are thrilled to participate in the Discovery on Target 2024 conference in Boston, taking place from September 30 to October 3!  We invite you to meet us at Poster Session A, where we will present our latest research at Poster Board #A18.    Join us to explore potential collaborations and stay informed about our groundbreaking innovations in Drug Discovery! #chemspace #openscience #research #science #drugdiscovery #chemicals #medicinalchemistry #drugdevelopment #chemistry #researchanddevelopment #chemicalindustry #science

If you were to look at a timeline of all drugs ever developed, you'd realize we are just scratching the surface with drug discovery. AI-enabled drug discovery is the start of exponential growth. The number of predicted realistic drug-like molecules ranges from 10^23 to 10^60, yet only about 10^8 substances have been synthesized to date. There's a vast gap between potential molecular diversity and what has been created. #DrugDiscovery #Chemistry #Research #Molecules

💡Do you want to learn more about #fragment-based drug discovery through structural biology, medicinal chemistry, and artificial intelligence? FragmentScreen is an initiative for fragment-based drug discovery that includes #canSERV_EU 🎗️partners EU-OPENSCREEN, ELIXIR and Instruct ERIC. Recently, they published about a fragment library for high-throughput screening. Do you want to make use of #fragmentscreening 🧪 and other research services? Then check out the canSERV open call website ➡️ https://lnkd.in/ejMQMds2 #researchservices #drugdiscovery #EUcancermission #EUbeatingcancerplan

Discovering the intricacies of drug targets is a vital step toward advancing precision medicine. In a study published in Science Advances, Professor Thomas Sakmar from The Rockefeller University used #MolBoolean to investigate the interactions between 215 cell surface receptors, targets of one-third of all FDA-approved drugs, and their associated proteins. WELCOME to join our Tech Talk at Cell Bio 2024 in San Diego, where Thomas Sakmar´s PhD student Yuanhuang (Harry) Chen will be a guest speaker. He will, together with our Product Manager Nancy Dekki Shalaly and Principal Scientist Mikael Malmqvist present our cutting-edge MolBoolean™ technology for in situ protein-protein interaction analysis. Learn more about #MolBoolean technology: https://ow.ly/qF6V50UpFOv #atlasantibodies #proteininteraction #proximityligation